Sequencing Controls Improve Confidence in NGS Patient Results

A conversation with Keith Cannon, Director Product Management, Horizon Discovery Ltd.

Advanced AI Technology for Clinical Genomic Support Across All Stages of Life

Adoption of clinical genomics applications has been driven by increasingly scalable genomic technologies. Higher-throughput approaches to genetic testing have resulted in increased diagnostic yields and discovery coupled with advances in bioinformatic analysis tools.

RNA, Data Science, and the Future of Precision Medicine

Q&A with Patrick Hurban, Q2 Solutions
Clinical OMICs Keynote Webinar lead image

Newborn Genomic Screening: In Sickness and In Health

In this inaugural Clinical OMICs Keynote webinar, we are proud to host two renowned leaders in the field of genomic medicine, Drs Stephen Kingsmore and Robert Green, who will discuss their pioneering work in the field of newborn genome sequencing and analysis.
Oxford Nanopore eBook cover

Clinical Research in a Real-Time Sequencing Age

Oxford Nanopore’s DNA/RNA sequencing technology delivers ultra-long reads (up to 2 Mb), enabling rapid and comprehensive analysis of variants. With devices scalable from portable to benchtop, nanopore sequencing offers a cost-effective solution to the challenges faced by traditional sequencing platforms.

From Bench to Clinic—The Potential of New Sequencing Tools

Sponsored content brought to you by As genome sequencing technology advances, researchers are increasingly exploring emerging tools for a host of potential clinical applications. Andrew...
Conceptual Circuit Intelligence

Mainstreaming Precision Oncology

Sponsored content brought to you by   What if every patient’s oncologist or lab testing personnel had access to an online digital encyclopedia of cancer mutations,...
Researchers Operating Chemistry Analyzer Machine

Better Understanding of Post-Translation Modifications Driving Innovation

Takeda has taken great strides in incorporating a patient-centric approach to drug development through the use of minimally invasive and less frequent testing procedures while maintaining the power and rigor of the clinical trial.

LeukoVantage: A Quest/QIAGEN Partnership Providing Clinical Insights Into Myeloid Malignancies

In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation.
Scroll Up